SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Non-TechICICI Ltd - (Nyse: IC)


Previous 10 
To: Labrador who wrote (489)8/9/2001 10:19:26 AM
From: Labrador
   of 494
 
By the way, the last quarterly results were 0.34 U.S. per NYSE ADR.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Labrador who wrote (490)8/14/2001 10:57:55 PM
From: Imran
   of 494
 
why is the stock so down? i bought earlier at 16, then saw it go up to the peak and down to 11, where i sold out.....

what are the prospects? earnings are still good..........

thx
imran

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Imran who wrote (491)8/15/2001 8:30:33 AM
From: Labrador
   of 494
 
It is so difficult to get good U.S. based accounting information on this company. I think that most people don't even bother with IC any more.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Labrador who wrote (492)8/15/2001 5:45:21 PM
From: Imran
   of 494
 
i guess so.......accounting in US GAAP seems to not be a priority..........but, do u think the fundamentals are there? steady divs and the indian govt will never let it go down....

imran

Share RecommendKeepReplyMark as Last Read


From: stevenmdart11/24/2009 6:54:33 AM
   of 494
 
Acquisitions and the Pharma industry

The Pharmaceutical industry has always been ruled by a selected number of ‘kings’, but now things are changing. New entrants are severely shaking their R & D models. Survival strategy - Instead of competing with them in research & development, the top 20 pharmaceutical companies are outsourcing the legwork to the new-borns. Not only to save around $7.5 billion annually (pharmaceutical industry) on an average, but also to save on the opportunity cost of generics replicating their formulas and selling products at huge discounts.

CytoDyn (CYDY) incorporated in 2003, has also come to the table with a revolutionary breakthrough: Cytolin. They claim it to be the only solution for HIV/AIDS (immune system therapy); and to prove it, studies of the drug will be designed and conducted by Massachusetts General Hospital. Past results of drug test on ten HIV infected subjects (carried out by company itself) were clearly evident of its efficacy and performance. But, once it gets through the study of Massachusetts General, more hype is expected, making it one of the hottest — yet one of the most classified — stocks in the biotech market.

What are your opinions regarding investment in such emerging
pharmaceutical companies? Comments, ideas or stock pick suggestions are welcome.

blog.insidecytolin.com

Share RecommendKeepReplyMark as Last Read
Previous 10